-
Something wrong with this record ?
Localized Insulin-Derived Amyloidosis in Diabetes Mellitus Type 1 Patient: A Case Report
J. Hrudka, E. Sticová, M. Krbcová, K. Schwarzmannová
Status not-indexed Language English Country Switzerland
Document type Case Reports
Grant support
Cooperatio Medical Diagnostics
Charles University
NLK
Directory of Open Access Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- Publication type
- Case Reports MeSH
Localized insulin-derived amyloidosis (LIDA) is a rare local complication of subcutaneous insulin application occurring in patients with diabetes type 1 and 2. A 45-year-old woman with an 11-year history of insulin-dependent diabetes mellitus type 1 underwent a mini-abdominoplasty and excision of a long-standing palpable mass in left hypogastric subcutaneous tissue in the area of long-term insulin application. Histopathological examination revealed insulin amyloidosis as a substrate of the mass lesion. Several months after surgery, there was a transient improvement in previously poor diabetes compensation. In addition to local allergic reactions, abscess formation, scarring, lipoatrophy/dystrophy, and lipohypertrophy, LIDA broadens the differential diagnostic spectrum of local insulin injection complications. LIDA has been described as a cause of poor glycemia compensation, probably due to the conversion of soluble insulin into insoluble amyloid fibrils, which prevents insulin from circulating in the blood and regulating glucose blood concentration. Improvement in diabetes compensation has been described in several reports, including our case. LIDA is a rare local complication of subcutaneous insulin application; accurate diagnosis and treatment have clinical consequences. Immunohistochemical or immunofluorescence distinction from other amyloid types is highly recommended.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23015683
- 003
- CZ-PrNML
- 005
- 20231020093545.0
- 007
- ta
- 008
- 231010s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/diagnostics13142415 $2 doi
- 035 __
- $a (PubMed)37510159
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hrudka, Jan $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic $1 https://orcid.org/0000000256494586
- 245 10
- $a Localized Insulin-Derived Amyloidosis in Diabetes Mellitus Type 1 Patient: A Case Report / $c J. Hrudka, E. Sticová, M. Krbcová, K. Schwarzmannová
- 520 9_
- $a Localized insulin-derived amyloidosis (LIDA) is a rare local complication of subcutaneous insulin application occurring in patients with diabetes type 1 and 2. A 45-year-old woman with an 11-year history of insulin-dependent diabetes mellitus type 1 underwent a mini-abdominoplasty and excision of a long-standing palpable mass in left hypogastric subcutaneous tissue in the area of long-term insulin application. Histopathological examination revealed insulin amyloidosis as a substrate of the mass lesion. Several months after surgery, there was a transient improvement in previously poor diabetes compensation. In addition to local allergic reactions, abscess formation, scarring, lipoatrophy/dystrophy, and lipohypertrophy, LIDA broadens the differential diagnostic spectrum of local insulin injection complications. LIDA has been described as a cause of poor glycemia compensation, probably due to the conversion of soluble insulin into insoluble amyloid fibrils, which prevents insulin from circulating in the blood and regulating glucose blood concentration. Improvement in diabetes compensation has been described in several reports, including our case. LIDA is a rare local complication of subcutaneous insulin application; accurate diagnosis and treatment have clinical consequences. Immunohistochemical or immunofluorescence distinction from other amyloid types is highly recommended.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Sticová, Eva $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
- 700 1_
- $a Krbcová, Magdaléna $u Department of Internal Medicine, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
- 700 1_
- $a Schwarzmannová, Klára $u Department of Plastic Surgery, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
- 773 0_
- $w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 13, č. 14 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37510159 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231010 $b ABA008
- 991 __
- $a 20231020093539 $b ABA008
- 999 __
- $a ok $b bmc $g 1997226 $s 1202045
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 13 $c 14 $e 20230720 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
- GRA __
- $a Cooperatio Medical Diagnostics $p Charles University
- LZP __
- $a Pubmed-20231010